Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-383 |
Synonyms | |
Therapy Description |
ABBV-383 (TNB-383B) is a bispecific antibody that targets alpha CD3 and BCMA, potentially resulting in the activation of T-cells and tumor cell lysis (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034, PMID: 36029527). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-383 | TNB-383B|TNB383B|TNB 383B|ABBV383|ABBV 383 | CD3 Antibody 74 TNFRSF17 Antibody 14 | ABBV-383 (TNB-383B) is a bispecific antibody that targets alpha CD3 and BCMA, potentially resulting in the activation of T-cells and tumor cell lysis (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034, PMID: 36029527). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05650632 | Phase I | ABBV-383 | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | Not yet recruiting | USA | FRA | 2 |
NCT03933735 | Phase I | ABBV-383 | A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | DEU | 0 |
NCT04453397 | Expanded access | ABBV-383 | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | No longer available | USA | 0 |